|
1
|
Kenneth Oh: Aberrant cytokine activity in the host immune response to COVID-19 leads to cytokine release syndrome; Bio-Rad Bulletin_7335; May, 2020. https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_7335.pdf.
|
|
2
|
Hanif M, Haider MA, Xi Q, Ali MJ and Ahmed MU: A review of the risk factors associated with poor outcomes in patients with coronavirus disease 2019. Cureus. 12(e10350)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Government of India Ministry of Health and Family Welfare: Clinical Management Protocol for COVID-19 (adults). https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf. Accessed, July 27, 2021.
|
|
4
|
Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, et al: Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology. 295(200463)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Falasca K, Ucciferri C, Brandimarte A, Auricchio A, Pontolillo M, Caiazzo L and Vecchiet J: Clinical characteristics and cardiovascular implications of the dead patients for COVID-19. Eur J Inflam. 19:2021.
|
|
6
|
Ali AHM, Mohamed SOO, Elkhidir IHE, Elbathani MEH, Ibrahim AAH, Elhassan ABE, Salman MST, Elhassan MAM, Elnil M and Abuzied AIH: The association of lymphocyte count, CRP, D-Dimer, and LDH with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Sudan J Med Sci. 15:9–23. 2020.
|
|
7
|
Büyükaydın B: The relationship of hemogram and inflammatory biomarkers to lenght of stay in hospital and clinical course in patients with COVID-19. Bezm Sci. 8:7–14. 2020.
|
|
8
|
Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M and Goodman M: Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One. 15(e0239802)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhao Y, Nie HX, Hu K, Wu XJ, Zhang YT, Wang MM, Wang T, Zheng SC, Li XC and Zeng SL: Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty. 9(108)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pourabdollah Toutkaboni M, Askari E and Khalili N, Tabarsi P, Jamaati H, Velayati AA, Dorudinia A, Rezaei M, Nadji SA, Mohamadnia A and Khalili N: Demographics, laboratory parameters and outcomes of 1061 patients with coronavirus disease 2019: A report from Tehran, Iran. New Microbe and New Infect. 38(100777)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kordzadeh-Kermani E, Khalili H and Karimzadeh I: Pathogenesis, clinical manifestations and complications of COVID-19. Future Microbiol. 15:1287–1305. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Thompson S, Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, Yuen KY, Mueller R, Koch D, Sethi S, et al: Horvath and the IFCC taskforce on COVID-19. IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients. Clin Chem Lab Med. 58:2009–2016. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A and Noubiap JJ: A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 8(37)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ucciferri C, Vecchiet J and Falasca K: Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases. 8:4280–4285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zenga F, Huangc Y, Guoa Y, Yina M, Chena X, Xiaod L and Deng G: Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 96:467–474. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jurado A, Martín MC, Abad-Molina C, Orduña A, Martínez A, Ocaña E, Yarce O, Navas AM, Trujillo A, Fernández L, et al: COVID-19: Age, interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 17(22)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Khourssaji M, Chapelle V, Evenepoel A, Belkhir L, Yombi JC, van Dievoet MA, Saussoy P, Coche E, Fillée C, Constantinescu SN, et al: A biological profile for diagnosis and outcome of COVID-19 patients. Clin Chem Lab Med. 58:2141–2150. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, Barassi A, Fontana L, Palumbo F, Garzia E, et al: Decreased serum level of sphingosine-1-phosphate: A novel predictor of clinical severity in COVID-19. EMBO Mol Med. 13(e13424)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hu H, Du H, Li J, Wang Y, Xu X, Wang C, Zhang Y, Zhang G, Zhao Y, Kang W and Lian J: Early prediction and identification for severe patients during the pandemic of COVID-19: A severe COVID-19 risk model constructed by multivariate logistic regression analysis. J Glob Health. 10(020510)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mirmohammadi S, Kianmehr A, Arefi M and Mahrooz A: Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran. New Microbes New Infect. 38(100792)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Alhenc-Gelas F and Drueke TB: Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. Kidney Int. 97:1091–1093. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang L, Peng Y, Zheng Q, Jiang L, Tang S and Chen P: Retrospective analysis of clinical characteristics and laboratory results of COVID-19 patients. European Journal of Inflammation. January 2021. doi:10.1177/20587392211011919.
|
|
23
|
Kho J, Ioannou A, Van den Abbeele K, Mandal AKJ and Missouris CG: Pulmonary embolism in COVID-19: Clinical characteristics and cardiac implications. Am J Emerg Med. 38:2142–2146. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K and Yatzkan G: Treatment of severe COVID-19 with Tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: A case report and literature review. Trop Med Infect Dis. 5(112)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Guillén L, Padilla S, Fernández M, Agulló V, García JA, Telenti G, García-Abellán J, Botella Á, Gutiérrez F and Masiá M: Preemptive interleukin-6 blockade in patients with COVID-19. Sci Rep. 10(16826)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A and Dagna L: Repurposing of biologic and targeted synthetic Anti-Rheumatic drugs in COVID-19 and Hyper-Inflammation: A comprehensive review of available and emerging evidence at the Peak of the Pandemic. Front Pharmacol. 11(598308)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X and Cao B: SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet. 395:1517–1520. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ponti G, Maccaferri M, Ruini C, Tomasi A and Ozben T: Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 57:389–399. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Huang I, Pranata R, Lim MA, Oehadian A and Alisjahbana B: C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. Ther Adv Respir Dis. 14(1753466620937175)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Weidmann MD, Ofori K and Rai AJ: Laboratory Biomarkers in the management of patients with COVID-19. Am J Clin Pathol. 155:333–342. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gris JC, Perez-Martin A, Quéré I and Sotto A: COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. Anaesth Crit Care Pain Med. 39:381–382. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yazdanpanah F, Hamblin MR and Rezaei N: The immune system and COVID-19: Friend or foe? Life Sci. 256(117900)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang L and Guo H: Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biomark Sci Technol. 2:1–23. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
South AM, Brady TM and Flynn JT: ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor blocker use during the Pandemic: The Pediatric perspective. Hypertension. 76:16–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, et al: A tool for early prediction of severe Coronavirus disease 2019 (COVID-19): A multicenter study using the risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 71:833–840. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adhikari IP, Tiwari R and Bala R: Estimation of the De Ritis ratio in the cases of chronic alcoholic liver disease attending OPD of a tertiary health care level institute of Kanpur, UP. PARIPEX-Indian J Res. 7:219–221. 2018.
|
|
37
|
Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, Akbari M, Heydari ST, Akbari H, Nowrouzi-Sohrabi P and Ahmadizar F: Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res. 25(30)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yazar H, Kayacan Y and Ozdin M: De Ritis ratio and biochemical parameters in COVID-19 patients. Arch Physiol Biochem. 1–5. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
|
|
39
|
Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, Zinellu E, Perra R, Madeddu G, Carru C, et al: The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. Eur J Clin Invest. 51(e13427)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Parmar KS, Singh GK, Gupta GP, Pathak T and Nayak S: Evaluation of De Ritis ratio in liver-associated diseases. Int J Med Sci Public Health. 5:1783–1788. 2016.
|
|
41
|
Qin C, Wei Y, Lyu X, Zhao B, Feng Y, Li T, Cao H, Yang X, Zhou X, Wang W, et al: High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients. Sci Rep. 10(16496)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Botros M and Sikaris KA: The de ritis ratio: The test of time. Clin Biochem Rev. 34:117–130. 2013.PubMed/NCBI
|
|
43
|
Varim C, Yaylaci S, Demirci T, Kaya T, Nalbant A, Dheir H, Senocak D, Kurt R, Cengiz H and Karacaer C: Neutrophil count to albumin ratio as a new predictor of mortality in patients with COVID-19 infection. Rev Assoc Med Bras (1992). 66 (Suppl 2):S77–S81. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ucciferri C, Caiazzo L, Di Nicola M, Borrelli P, Pontolillo M, Auricchio A, Vecchiet J and Falasca K: Parameters associated with diagnosis of COVID-19 in emergency department. Immun Inflamm Dis. 9:851–861. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kabak M, Çil B and Hocanlı I: Relationship between leukocyte, neutrophil, lymphocyte, platelet counts, and neutrophil to lymphocyte ratio and polymerase chain reaction positivity. Int Immunopharmacol. 93(107390)2021.PubMed/NCBI View Article : Google Scholar
|
